DALLAS, April 05, 2018 (GLOBE NEWSWIRE) -- Nexeon MedSystems Inc (”Nexeon”) (OTCQB:NXNN) a neurostimulation medical device company, announced today financial results for the fourth quarter and full year ended December 31, 2017.
Topics: Nexeon Financial News
Human brains have to manage an inconceivably massive amount of information. By current estimations, we are offloading, transferring, and storing information upward of 2.5 quintillion bytes a day. In this, humans require a trustable mechanism for recalling and telling their story. And such technology could enable the betterment of the human species.
Topics: Implantable Devices
Nexeon MedSystems Inc., headquartered in Dallas, Texas, is a medical device company developing a neurostimulator technology platform for the treatment of disorders through the electrical stimulation of neural tissues. The company’s first application of its Nexeon Neurostimulation System will be for the treatment of chronic medical conditions such as Parkinson’s and associated diseases in Europe. The company’s Belgian-based Medi-Line subsidiary provides global medical device outsource manufacturing solutions for existing customers and long term supply contracts with Fortune 50 companies.
Nexeon Medsytems is a medical device company focused on providing innovative neurostimulation products for patients suffering from debilitating neurological diseases, including Parkinson’s and essential tremor. It was founded in 2005 with the goal of changing how innovative ideas in the medical device industry move from concept to reality, with a focus on creating solutions for clinicians in their pursuit of improving patient outcomes.
NEW YORK, NY / ACCESSWIRE / December 21, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Nexeon MedSystems, Inc. (OTCQB: NXNN).
Topics: Analyst Coverage
Nexeon MedSystems (OTCQB: NXNN) announced today a conference call to discuss 2017 results. The call is scheduled for 4:00 p.m. Central Standard Time on November 20th, 2017. Analysts, investors, and other interested parties may access via conference line (https://www.uberconference.com/nexeon) or dialing an optional dial in number: 469-551-9824. The call will also be archived on the Company investor relations page.
Topics: Conference Call
Feasibility Study for Treatment of Atrial Fibrillation is First Phase of €3.4M BioWin Award
Normally an acquisition and commencing a clinical trial are productive events for a small company, especially those in the hot "medtech" sector, but that hasn't been the case for Nexeon MedSystems Inc. (OTCQB:NXNN). The Belgium-based bioelectronics medical device company with an emphasis on neurological diseases has seen shares slide since they began trading less than a month ago from $2.00 each to under $1.00.
Nexeon MedSystems Inc (OTC:QB “NXNN”) announced today that it has received a Phase I Small Business Research Innovation (SBIR) grant from the National Heart, Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), to develop a neurostimulation therapy for asthma in collaboration with researchers at Oregon Health Sciences University. The funding award was granted due to the merits of the proposed development plan for a novel asthma treatment related to airway constriction. This therapy would be a second-line defense for patients whose current medications do not adequately treat their asthma.
Dallas, TX -- Nexeon MedSystems, Inc. (OTC:QB NXNN) announced today that it has commenced "regular way" trading on the OTC Market (OTC:QB) under the symbol "NXNN". The Company is finalizing development of its deep brain stimulation system for the treatment of symptoms associated with Parkinson's disease.
Topics: Nexeon Financial News